CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 22 enrolled
Drug / intervention
statin +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01702987
NCT01702987N/ACompleted
CompareCT.gov

Evaluation of Ubiquinol on the Association of Statins and Mitochondrial Oxidative Capacity Using 31P Magnetic Resonance Imaging

Beth Israel Deaconess Medical Center·interventional·Posted Oct 10, 2012·Updated Apr 17, 2017

In Brief

A clinical study evaluating ubiquinol, placebo, and 1 other intervention for Myopathy and 2 related conditions. Completed, enrolled 22 participants across 1 site.

Detailed Summary

It is our primary hypothesis that statin drugs impair skeletal muscle mitochondrial function and that ubiquinol (the reduced active form of CoQ10) supplementation will block impairment of PCr recovery kinetics in patients using statins. The investigators propose a pilot study to extend our research to examine PCr recovery kinetics in 20 statin users randomized in a parallel arm study to either ubiquinol or placebo over 4 weeks.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyopathy, HMG COA Reductase Inhibitor Adverse Reaction, Hypercholesterolemia
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedOct 10, 2012
Enrollment StartOct 1, 2012
Primary CompletionOct 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 13.7 years ago

Interventions

ubiquinoldietary

ubiquinol supplementation was given for 1 month to 12 patients

placebodietary

placebo (identical in appearance to ubiquinol) was given for 1 month to 9 patients

statindrug

statin was given for 1 month to 21 patients